CEO: Rudi Pauwels

Advent Contact: Raj Parekh

Point-of-care molecular diagnostics instrumentation

Biocartis is a commercial stage company which develops novel molecular diagnostics. The proprietary Idylla™ platform is a fully automated, real-time system which provides accurate, highly-reliable RNA and protein expression information from any biological sample, thus improving diagnosis and facilitating personalised therapy at the point of care.

Advent invested in the Series A in 2009. Biocartis listed on Euronext Brussels in 2015 (EBR:BCART).